Request Appointment
710 W 168th StNew York, NY 10032
Fax+1 212-305-1304
Overview of Dr. Hirano
Dr. Michio Hirano is a neurologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital and NewYork-Presbyterian/Columbia University Irving Medical Center. He received his medical degree from Albert Einstein College of Medicine and has been in practice 40 years. Dr. Hirano accepts several types of health insurance, listed below. He is one of 514 doctors at New York-Presbyterian Hospital and one of 233 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Neurology. He has more than 100 publications and over 500 citings.
Education & Training
New York Presbyterian Hospital (Columbia Campus)Residency, Neurology, 1987 - 1990
Jacobi Medical CenterInternship, Transitional Year, 1986 - 1987
Albert Einstein College of MedicineClass of 1986- New York Presbyterian Hospital (Cornell Campus)Fellowship, Neuromuscular Medicine (Neurology)
Certifications & Licensure
FL State Medical License 2023 - Present
NJ State Medical License 2017 - 2027
NY State Medical License 1987 - 2026
American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification NYP Quality Analytics, Ambulatory, NewYork-Presbyterian Hospital, 2014-2017
- CMS Meaningful Use Stage 1 Certification Allscripts TouchWorks EHR, Allscripts, 2014-2017
- CMS Meaningful Use Stage 2 Certification Allscripts TouchWorks EHR (Complete), Allscripts, 2014-2017
Clinical Trials
- Study of Idebenone in the Treatment of Mitochondrial Encephalopathy Lactic Acidosis & Stroke-like Episodes Start of enrollment: 2009 May 01
- North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC) Start of enrollment: 2011 Jan 31
- The Natural History Study of Mitochondrial NeuroGastroIntestinal Encephalopathy (MNGIE)
Publications & Presentations
PubMed
- Rhabdomyolysis due to mtDNA pathogenic variants: Report of a subject with a novel MT-CO3 variant and review of the literature.Emanuele Barca, Nuri Jacoby, Ali Naini, Michael L Miller, Valentina Emmanuele
Molecular Genetics and Metabolism. 2026-03-01 - 4,5-dihydroxyhexanoic acid is a robust circulating and urine marker of mitochondrial disease and its severity.Owen S Skinner, Maria Miranda, Fangcong Dong, Tessa Struhl, Melissa A Walker
Biorxiv. 2026-02-12 - Clinical and Genotypic Spectrum of Twinkle-Related Disorders: Insights From a Multinational Cohort Study.Piervito Lopriore, Zeynep Ünlütürk, Thomas Klopstock, Amel Karaa, Cecile Rouzier
Neurology. 2026-02-10
Journal Articles
- A Novel Complex Neurological Phenotype Due to a Homozygous Mutation in FDX2Michio Hirano, MD, Brain
Press Mentions
UCB Drug Becomes First FDA-Approved Treatment for Ultra-Rare and Fatal Mitochondrial DiseaseNovember 5th, 2025- Stress Alters Metabolic Hormone with Health Consequences, Study ShowsOctober 14th, 2025
- Senior Researcher Spotlight: Fernando Scaglia Explores Novel Therapeutic Approaches for Mitochondrial DisordersJune 7th, 2022
Grant Support
- The North American Mitochondrial Disease Consortium (NAMDC)COLUMBIA UNIVERSITY HEALTH SCIENCES2011–2025
Professional Memberships
- Member
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
Great West PPOHealthfirst New York
HIP of New York - Select PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
